Dr. Ajay Singh (right), who oversaw a trial of the drug Procrit and was surprised by the negative results, is shown with (from left), Dr. Jeremy Duffield, Dr. Emily Schopick, and nurse Patricia Sullivan during rounds at Brigham and Women's Hospital.
(DAVID KAMERMAN/GLOBE STAFF)
Amid warnings, Partners to cut anemia drug doses
Higher use tied to death risk
Dr. Ajay Singh (right), who oversaw a trial of the drug Procrit and was surprised by the negative results, is shown with (from left), Dr. Jeremy Duffield, Dr. Emily Schopick, and nurse Patricia Sullivan during rounds at Brigham and Women's Hospital.
(DAVID KAMERMAN/GLOBE STAFF)
Boston's largest hospital system, Partners HealthCare , says it plans to reduce doses of antianemia drugs given to kidney disease and chemotherapy patients in response to warnings that aggressive use increases the risk of fatal heart attacks and strokes. (Full article: 1066 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
